Literature DB >> 35988104

The role of FASL, BCL-2 and BAX polymorphisms in brazilian patients with prostate cancer and benign prostatic hyperplasia.

Gabriela Kniphoff da Silva Lawisch1,2, Vanderlei Biolchi1, Gabriela Kaufmann1, Gabriela Nicolai1, Eduarda Capitaneo1, Thais Regina Rosembach1, Janaina Zang1,2, Ilma Simoni Brum2, José Artur Bogo Chies3,4.   

Abstract

BACKGROUND: Prostate cancer (PCA) is one of the leading causes of death among men, being related to several factors, including the aging male population, like benign prostatic hyperplasia (BPH), a histopathological and hyperplastic alteration associated to prostate aging. The FASL, BCL-2 and BAX genes are involved in cell apoptosis regulation and can be related to the development of both cancer and hyperplasia. This study aimed to investigate the association of FASL - 844 (rs763110), BCL-2 -938 (rs2279115) and BAX - 248 (rs4645878) polymorphic variants in Southern Brazilian PCA and BPH patients and healthy controls. METHODS AND
RESULTS: 348 samples were analyzed, being 123 from PCA patients, 143 BPH patients and 82 healthy controls, using PCR-RFLP techniques. The results of genotyping analysis were adjusted by age, and compared with PSA levels and prostate volume. The analyzes of genotype frequencies according to PCA, HPB and controls, were performed by logistic regression corrected by age, and showed that the FASL CC genotype can be a risk factor for PCA patients, when compared to controls (p = 0.041). The clinical data investigation indicated higher PSA levels in PCA patients with FASL CC genotype, as compared to TC genotype carriers (p = 0.044), higher PSA levels for healthy individuals with BCL-2 AA genotype, comparing with CC genotype (p = 0.027) and higher PSA levels in BPH group with FASL CC genotype, as compared to TC genotype (p = 0.044).
CONCLUSIONS: Our data indicate the FASLCC genotype as a risk factor for prostate pathologies, whileBCL-2 CC can act as a protective genotype.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Apoptosis; BAX; BCL-2; Benign prostatic hyperplasia; FASl; Prostate cancer

Mesh:

Substances:

Year:  2022        PMID: 35988104     DOI: 10.1007/s11033-022-07805-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  29 in total

1.  The role of the bax gene polymorphism G(-248)A in chronic lymphocytic leukemia.

Authors:  C Fegan; J Starczynski; G Pratt; C Pepper
Journal:  Leukemia       Date:  2006-06-08       Impact factor: 11.528

2.  FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China.

Authors:  Meilin Wang; Dongmei Wu; Ming Tan; Weida Gong; Hengchuan Xue; Hongbin Shen; Zhengdong Zhang
Journal:  Biochem Genet       Date:  2009-06-30       Impact factor: 1.890

Review 3.  Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Faris Alrumaihi; Nahlah Makki Almansour; Fahad M Aldakheel; Rafiq Ahmad Rather; Dil Afroze; Bilal Rah
Journal:  Am J Transl Res       Date:  2021-04-15       Impact factor: 4.060

4.  Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.

Authors:  Holger Nückel; Ulrich H Frey; Maja Bau; Ludger Sellmann; Jens Stanelle; Jan Dürig; Karl-Heinz Jöckel; Ulrich Dührsen; Winfried Siffert
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

Review 5.  Mechanistic targets for BPH and prostate cancer-a review.

Authors:  Abhishek Shah; Aarti Abhishek Shah; Nandakumar K; Richard Lobo
Journal:  Rev Environ Health       Date:  2020-09-22       Impact factor: 3.458

6.  Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.

Authors:  Hiroshi Hirata; Yuji Hinoda; Nobuyuki Kikuno; Yutaka Suehiro; Varahram Shahryari; Ardalan E Ahmad; Z Laura Tabatabai; Mikio Igawa; Rajvir Dahiya
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

7.  CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.

Authors:  Francis Maria Báo Zambra; Vanderlei Biolchi; Ilma Simoni Brum; José Artur Bogo Chies
Journal:  Hum Immunol       Date:  2013-04-28       Impact factor: 2.850

8.  BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility.

Authors:  Ning Zhang; Xiaoyan Li; Kai Tao; Liyu Jiang; Tingting Ma; Shi Yan; Cunzhong Yuan; Meena S Moran; Faming Liang; Bruce G Haffty; Qifeng Yang
Journal:  BMC Med Genet       Date:  2011-04-01       Impact factor: 2.103

Review 9.  Apoptosis in cancer: from pathogenesis to treatment.

Authors:  Rebecca S Y Wong
Journal:  J Exp Clin Cancer Res       Date:  2011-09-26

10.  Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019.

Authors:  Xiao-Feng Xu; Guo-Xiong Liu; Ya-Shou Guo; Hai-Yun Zhu; Da-Lin He; Xi-Min Qiao; Xu-Hui Li
Journal:  Am J Mens Health       Date:  2021 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.